levodopa

Summary

Summary: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Top Publications

  1. doi Parkinson's disease: levodopa-induced dyskinesia and signal transduction
    Emanuela Santini
    Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
    FEBS J 275:1392-9. 2008
  2. doi Systematic review of levodopa dose equivalency reporting in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Mov Disord 25:2649-53. 2010
  3. ncbi Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease
    Paul Krack
    Department of Clinical and Biological Neurosciences, Joseph Fourier University, Grenoble, France
    N Engl J Med 349:1925-34. 2003
  4. ncbi Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    J E Ahlskog
    Department of Neurology, Mayo Clinic, 200 First Street S.W, Rochester, MN 55905, USA
    Mov Disord 16:448-58. 2001
  5. ncbi Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease
    Roshan Cools
    Helen Wills Neuroscience Institute, University of California, 132 Barker Hall, Berkeley, USA
    Neurosci Biobehav Rev 30:1-23. 2006
  6. pmc Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
    Mathias Pessiglione
    Wellcome Department of Imaging Neuroscience, 12 Queen Square, London WC1N 3BG, UK
    Nature 442:1042-5. 2006
  7. doi Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study
    Eduard Kraft
    Department of Neurology, University of Ulm, Ulm, Germany
    Parkinsonism Relat Disord 15:558-63. 2009
  8. pmc Dosage-dependent non-linear effect of L-dopa on human motor cortex plasticity
    Katia Monte-Silva
    Department of Clinical Neurophysiology, Georg August University Gottingen, Robert Koch Strasse 40, 37099 Gottingen, Germany
    J Physiol 588:3415-24. 2010
  9. ncbi Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease
    Andrea A Kuhn
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London WCIN 3BG, UK
    Eur J Neurosci 23:1956-60. 2006
  10. ncbi L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
    M A Cenci
    Wallenberg Neuroscience Center, Institute of Physiology and Neuroscience, University of Lund, 223 62 Lund, Sweden
    Eur J Neurosci 10:2694-706. 1998

Research Grants

  1. Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and Disease
    John J Mieyal; Fiscal Year: 2012
  2. A Phase II Trial of Levodopa in Angelman Syndrome
    Wen Hann Tan; Fiscal Year: 2013
  3. Miguel A L Nicolelis; Fiscal Year: 2014
  4. A Conserved G-rich Region within Human TH Promoter Regulates Its Activity
    Soumitra Basu; Fiscal Year: 2011
  5. Characterization of Striatal Nitric Oxide Signaling
    Anthony West; Fiscal Year: 2009
  6. Neural Substrates of Oral Motor Dysfunction in Parkinson's Disease
    EMILY KATE PRINE; Fiscal Year: 2010
  7. A Novel Monkey Model for Parkinson's Drug Discovery
    Howard J Federoff; Fiscal Year: 2010
  8. KATHRYN ANNE CHUNG; Fiscal Year: 2014
  9. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2012
  10. JOY MARIE SCHMITZ; Fiscal Year: 2014

Detail Information

Publications364 found, 100 shown here

  1. doi Parkinson's disease: levodopa-induced dyskinesia and signal transduction
    Emanuela Santini
    Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
    FEBS J 275:1392-9. 2008
    ..The role of this pathological adaptation and of the consequent changes in signaling in the development and expression of LID are discussed...
  2. doi Systematic review of levodopa dose equivalency reporting in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Mov Disord 25:2649-53. 2010
    ..drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications...
  3. ncbi Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease
    Paul Krack
    Department of Clinical and Biological Neurosciences, Joseph Fourier University, Grenoble, France
    N Engl J Med 349:1925-34. 2003
    ..Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown...
  4. ncbi Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    J E Ahlskog
    Department of Neurology, Mayo Clinic, 200 First Street S.W, Rochester, MN 55905, USA
    Mov Disord 16:448-58. 2001
    ..consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD)...
  5. ncbi Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease
    Roshan Cools
    Helen Wills Neuroscience Institute, University of California, 132 Barker Hall, Berkeley, USA
    Neurosci Biobehav Rev 30:1-23. 2006
    ....
  6. pmc Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
    Mathias Pessiglione
    Wellcome Department of Imaging Neuroscience, 12 Queen Square, London WC1N 3BG, UK
    Nature 442:1042-5. 2006
    ..We conclude that dopamine-dependent modulation of striatal activity can account for how the human brain uses reward prediction errors to improve future decisions...
  7. doi Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study
    Eduard Kraft
    Department of Neurology, University of Ulm, Ulm, Germany
    Parkinsonism Relat Disord 15:558-63. 2009
    To assess the effect of a single levodopa dose (200 mg levodopa, 50 mg carbidopa=sdLD) on cortical and subcortical motor-circuit activation during bimanual grip force in patients with Parkinson's disease (PD).
  8. pmc Dosage-dependent non-linear effect of L-dopa on human motor cortex plasticity
    Katia Monte-Silva
    Department of Clinical Neurophysiology, Georg August University Gottingen, Robert Koch Strasse 40, 37099 Gottingen, Germany
    J Physiol 588:3415-24. 2010
    ..This might be important for the therapeutic application of dopaminergic agents, especially for rehabilitative purposes, and explain some opposing results in former studies...
  9. ncbi Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease
    Andrea A Kuhn
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London WCIN 3BG, UK
    Eur J Neurosci 23:1956-60. 2006
    ..correlations between the suppression of synchronization at 8-35 Hz in STN and the reduction in Parkinsonism with levodopa. LFPs were recorded on and off medication from STN deep-brain stimulation electrodes in nine PD patients...
  10. ncbi L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
    M A Cenci
    Wallenberg Neuroscience Center, Institute of Physiology and Neuroscience, University of Lund, 223 62 Lund, Sweden
    Eur J Neurosci 10:2694-706. 1998
    ..Due to its treatment-dependent expression, and strong correlation with the associated dyskinetic symptoms, striatal PDyn mRNA, in particular, may play a role in the mechanisms of behavioural sensitization brought about by the drug...
  11. pmc Improvement of memory guided saccades in parkinsonian patients by high frequency subthalamic nucleus stimulation
    S Rivaud-Pechoux
    INSERM U289, Hopital de la Salpetriere, 47 bd de l Hopital, 75651 Paris Cedex 13, France
    J Neurol Neurosurg Psychiatry 68:381-4. 2000
    ..This study shows that, by contrast with levodopa, STN stimulation improves memory guided saccade deficits, and illustrates for the first time in humans the role ..
  12. ncbi Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication
    R Swainson
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge, UK
    Neuropsychologia 38:596-612. 2000
    ....
  13. ncbi Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study
    K Scheidtmann
    Neurologische Klinik, D 83043 Bad, Aibling, Germany
    Lancet 358:787-90. 2001
    ..Our aim was to ascertain whether levodopa could enhance the efficacy of physiotherapy after hemiplegia.
  14. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  15. ncbi Dopamine depletion impairs precursor cell proliferation in Parkinson disease
    Günter U Höglinger
    INSERM U289 Hôpital de la Salpetrière, F 75651 Paris, France
    Nat Neurosci 7:726-35. 2004
    ..These observations suggest that the generation of neural precursor cells is impaired in Parkinson disease as a consequence of dopaminergic denervation...
  16. doi Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    J Neural Transm (Vienna) 118:1661-90. 2011
    ..proportion of patients with Parkinson's disease (PD) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment...
  17. ncbi Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
    Manolo Carta
    Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Brain 130:1819-33. 2007
    ....
  18. ncbi Impact of the motor complications of Parkinson's disease on the quality of life
    Stéphane Chapuis
    Service de Neurologie, Centre Hospitalier Vichy, France
    Mov Disord 20:224-30. 2005
    The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD...
  19. doi L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia
    Hanna S Lindgren
    Basal Ganglia Pathophysiology, Department of Experimental Medical Science, Lund University, Lund, Sweden
    J Neurochem 112:1465-76. 2010
    ..The present results indicate that both a high DA release post-L-DOPA administration and an increased responsiveness to DA must coexist for a full expression of dyskinesia...
  20. doi Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia
    Daniella Rylander
    Basal Ganglia Pathophysiology Laboratory, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Ann Neurol 68:619-28. 2010
    Striatal serotonin projections have been implicated in levodopa-induced dyskinesia by providing an unregulated source of dopamine release...
  21. ncbi Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?
    J Tassin
    INSERM U289, Hopital de la Salpetriere, Paris, France
    Brain 123:1112-21. 2000
    ..We studied 22 families with a phenotype of levodopa-responsive dystonia by sequencing the six coding exons, the 5'-untranslated region and the exon-intron boundaries ..
  22. ncbi Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes
    Galit Kleiner-Fisman
    Parkinson s Disease Research Education and Clinical Center, Philadelphia VA Hospital, Philadelphia, Pennsylvania 19104, USA
    Mov Disord 21:S290-304. 2006
    ..These data provide an estimate of the magnitude of the treatment effects and emphasize the need for controlled and randomized studies...
  23. doi Chronic intermittent L-DOPA treatment induces changes in dopamine release
    Martin Lundblad
    Department of Integrative Medical Biology, Umea University, Sweden
    J Neurochem 108:998-1008. 2009
    ..This indicates the importance of studying DA release dynamics for the understanding of both beneficial and adverse effects of l-DOPA replacement therapy...
  24. doi Modulatory effects of levodopa on cognitive control in young but not in older subjects: a pharmacological fMRI study
    Ozgür A Onur
    Cologne University, Germany
    J Cogn Neurosci 23:2797-810. 2011
    ..In a double-blind, placebo-controlled within-subject design, subjects were measured after levodopa (100 mg) or placebo administration...
  25. doi Does levodopa accelerate the pathologic process in Parkinson disease brain?
    L Parkkinen
    Queen Square Brain Bank for Neurological Disorders, UCL Institute of Neurology, UK
    Neurology 77:1420-6. 2011
    Several in vitro studies have suggested levodopa (L-dopa) to be toxic to dopaminergic neurons and that it can modulate the aggregation process of α-synuclein...
  26. doi In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
    Flora Mela
    Department of Experimental and Clinical Medicine, Section of Pharmacology, Center for Neuroscience and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy
    Neurobiol Dis 45:573-82. 2012
    Evidence for an involvement of striatal D1 receptors in levodopa-induced dyskinesia has been presented whereas the contribution of striatal D2 receptors remains controversial...
  27. doi Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa
    Fabrizio Esposito
    Department of Neuroscience, University of Naples Federico II, Via S Pansini 5, 80131 Naples, Italy
    Brain 136:710-25. 2013
    ..disease is mainly characterized by a dysfunction of the sensorimotor pathways, which can be influenced by levodopa administration, the present study investigated the functional connectivity changes within the sensorimotor ..
  28. pmc Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent
    Aminu Umar Kura
    Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
    Int J Nanomedicine 8:1103-10. 2013
    ..nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a ..
  29. ncbi Motivation, reward, and Parkinson's disease: influence of dopatherapy
    V Czernecki
    INSERM E 007, Hopital de la Salpetriere, Paris, France
    Neuropsychologia 40:2257-67. 2002
    ....
  30. ncbi Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-..
  31. pmc Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment
    M Rafiuddin Ahmed
    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Neurochem 104:1622-36. 2008
    ..The data suggest that alterations in the expression and subcellular distribution of arrestins and GRKs contribute to pathophysiology of Parkinson's disease. Thus, these proteins may be targets for antiparkinsonian therapy...
  32. doi Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
    Ray L Watts
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0017, USA
    Mov Disord 25:858-66. 2010
    b>Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD)...
  33. doi AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials
    Daniela Berg
    University of Tubingen, Hertie Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tubingen, Germany
    Mov Disord 26:1243-50. 2011
    ..objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia...
  34. ncbi Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism
    Michael J Frank
    Department of Psychology and Program in Neuroscience, University of Arizona, Tucson, AZ 85721, USA
    Science 318:1309-12. 2007
    ..These findings implicate independent mechanisms leading to impulsivity in treated Parkinson's patients and were predicted by a single neurocomputational model of the basal ganglia...
  35. pmc Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease
    Tomas Bjorklund
    Brain Repair and Imaging in Neural Systems, 22184 Lund, Sweden
    Brain 133:496-511. 2010
    ..Taken together these results show that vector-mediated continuous 3,4-dihydroxyphenylalanine delivery has the potential to provide significant symptomatic relief even in advanced stages of Parkinson's disease...
  36. ncbi Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech
    Serge Pinto
    Neurosciences Précliniques, INSERM Unité 318, Grenoble, France
    Mov Disord 20:1507-15. 2005
    b>Levodopa (L-dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD)...
  37. ncbi Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease
    J D Schaafsma
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Neurol 10:391-8. 2003
    To assess the effect of levodopa on distinct freezing of gait (FOG) subtypes in patients with 'off' FOG. Nineteen patients (12 men, mean age 62.0 +/- 8...
  38. ncbi Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
    M Lundblad
    Department of Physiological Sciences, Wallenberg Neuroscience Centre, Neurobiology Division, Lund University, BMC A11, S 221 84 Lund, Sweden
    Eur J Neurosci 15:120-32. 2002
    ..Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments...
  39. doi Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Arch Neurol 67:589-95. 2010
    ..An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies...
  40. ncbi Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Brain 125:584-94. 2002
    ..These data suggest that L-dopa ameliorates high-level cognitive deficits in Parkinson's disease by inducing relative blood flow changes in the right dorsolateral prefrontal cortex...
  41. ncbi Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease
    Moran Weinberger
    Department of Physiology, Med Sci Building 3302, 1 King s College Circle, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 96:3248-56. 2006
    ..The study also suggests that LFP beta oscillatory activity is generated largely within the dorsal portion of the STN and can produce synchronous oscillatory activity of the local neuronal population...
  42. pmc Action controls dopaminergic enhancement of reward representations
    Marc Guitart-Masip
    Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom
    Proc Natl Acad Sci U S A 109:7511-6. 2012
    ..Thus, increasing dopamine levels with levodopa selectively boosted striatal and substantia nigra/ventral tegmental representations associated with actions ..
  43. ncbi Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
    ..that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients...
  44. ncbi Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
    Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease...
  45. doi Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 23:2177-85. 2008
    ..the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations...
  46. ncbi Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa
    Joanna D Schaafsma
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel
    J Neurol Sci 212:47-53. 2003
    ..to falls, we quantitatively evaluated: (1) the relationship between gait variability (a marker of fall risk in other populations), fall history, and other parkinsonian features, and (2) the effects of levodopa on these relationships.
  47. ncbi Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Neurology 64:216-23. 2005
    To compare daytime intraduodenal levodopa/carbidopa infusion as monotherapy with individually optimized conventional combination therapies in patients with advanced Parkinson disease (PD) for motor fluctuations and quality of life (QoL).
  48. pmc Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition
    J B Rowe
    University of Cambridge Department of Clinical Neurosciences, Cambridge, CB2 7EF, UK
    Brain 131:2094-105. 2008
    ..We discuss the implications for investigation and optimal treatment of this common condition at different stages of disease...
  49. ncbi ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice
    Nancy Pavon
    Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    Biol Psychiatry 59:64-74. 2006
    ..We have developed a model of L-DOPA-induced dyskinesias in mice that reproduces the main clinical features of dyskinesia in humans...
  50. doi Molecular mechanisms of L-DOPA-induced dyskinesia
    Peter Jenner
    King s College London, Guy s Campus, School of Health and Biomedical Sciences, London SE1 1UL, UK
    Nat Rev Neurosci 9:665-77. 2008
    ..The combination of nigral denervation and drug treatment establishes inappropriate signalling between the motor cortex and the striatum, leading to persistent dyskinesia...
  51. ncbi Regulation of dopamine quantal size in midbrain and hippocampal neurons
    Emmanuel N Pothos
    Department of Pharmacology and Experimental Therapeutics and Neuroscience, Room 201, Medical and Veterinary Building, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Behav Brain Res 130:203-7. 2002
    ..We suggest that plasticity in dopamine quantal seems likely to be involved in both normal synaptic modification and disease states...
  52. ncbi Movement-related changes in synchronization in the human basal ganglia
    Michael Cassidy
    Sobell Department of Neurophysiology, Institute of Neurology, Queen Square, London, UK
    Brain 125:1235-46. 2002
    ..This organization is critically dependent on the level of dopaminergic activity...
  53. ncbi Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
    Masato Asanuma
    Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Neurotox Res 5:165-76. 2003
    ....
  54. ncbi Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease
    S Robelet
    Interactions Cellulaires, Neurodégénérescence et Neuroplasticité, UMR 6186, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France
    Eur J Neurosci 20:1255-66. 2004
    ..The L-DOPA-induced overexpression of GLT1 may represent a compensatory mechanism involving astrocytes to limit glutamate overactivity and subsequent toxic processes...
  55. ncbi Clinical practice. Diagnosis and initial management of Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, Portland 97239, USA
    N Engl J Med 353:1021-7. 2005
  56. ncbi Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade)
    Jagdish C Sharma
    Parkinson s Disease Services, Sherwood Forest Hospitals NHS Trust, Bournemouth, BH7 7 DW, UK
    Parkinsonism Relat Disord 12:499-505. 2006
    ..The dyskinetic patients received significantly higher maximum level daily dose of levodopa. These patients had lost weight during the course of the disease from 72+/-15 to 66+/-17kg, p=0.002...
  57. ncbi Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
    P A Kempster
    Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College, London, UK
    Brain 130:2123-8. 2007
    Patients with Parkinson's disease who develop disabling levodopa-induced motor fluctuations have a stronger therapeutic response than those who experience a more modest but stable response...
  58. doi Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease
    M U Ferraye
    Université de Grenoble, INSERM U836, CHU de Grenoble, Pavillon de Neurologie, BP 217, 38043 Grenoble Cedex 9, France
    Neurology 70:1431-7. 2008
    We studied the effects of subthalamic nucleus (STN) stimulation vs levodopa on freezing of gait (FOG) and gait impairments in a large consecutive series of patients with Parkinson disease with bilateral STN stimulation.
  59. doi Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications
    Karla Eggert
    Department of Neurology, Philipps University of Marburg, Marburg, Germany
    Clin Neuropharmacol 31:151-66. 2008
    We report here on the experience with continuous jejunal levodopa infusion in 13 German parkinsonian patients who have motor and nonmotor complications despite individually optimized oral treatment...
  60. doi Levodopa affects functional brain networks in Parkinsonian resting tremor
    Bettina Pollok
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Mov Disord 24:91-8. 2009
    ..To shed light on the effect of levodopa on these network interactions, we investigated 10 patients with tremor-dominant PD and reanalyzed data in 11 ..
  61. doi Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum
    Min Kong
    Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 1665 Kongjiang Road, 200092 Shanghai, People s Republic of China
    Neurochem Res 34:1513-21. 2009
    ..To elucidate molecular mechanisms that underlie the persisting alterations in motor response occurring with levodopa treatment of parkinsonian patients, we evaluated the effects of unilateral nigrostriatal depletion with 6-..
  62. doi Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease
    Cory Toth
    Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Ann Neurol 68:28-36. 2010
    ..We sought to examine the prevalence of PN in a population of IPD patients and a potential relationship to levodopa use and fasting methylmalonic acid (MMA) levels.
  63. doi Levodopa analgesia in experimental neuropathic pain
    Nuria Cobacho
    Servicio de Neurobiología Investigación, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, 28034 Madrid, Spain
    Brain Res Bull 83:304-9. 2010
    b>Levodopa has been shown to produce analgesia in various clinical and experimental settings, but its use for chronic pain treatment has not been established...
  64. doi Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
    Paolo Calabresi
    Clinica Neurologica, Universita degli Studi di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
    Lancet Neurol 9:1106-17. 2010
    b>Levodopa is the most effective drug for the treatment of Parkinson's disease. However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias...
  65. doi Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
    Imtiaz Ahmed
    Centre for Neuroscience, Imperial College, London, UK
    Brain 134:979-86. 2011
    b>Levodopa-induced dyskinesias are a common complication of long-term therapy in Parkinson's disease...
  66. doi Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study
    Antonio Cerasa
    Neuroimaging Research Unit, Institute of Neurological Sciences, National Research Council, Germaneto CZ, Italy
    Mov Disord 26:807-12. 2011
    b>Levodopa-induced dyskinesias represent disabling complications from long-term therapy with dopaminergic drugs for treating Parkinson's disease (PD)...
  67. pmc Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia
    Nina Nevalainen
    Integrative Medical Biology, Umea University, Umea, Sweden
    J Neurochem 118:12-23. 2011
    ..Thus, the dopamine overflow produced from the serotonergic nerve fibers appears not to be the major cause of dyskinetic behavior...
  68. doi Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial
    Robert E Gross
    Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA
    Lancet Neurol 10:509-19. 2011
    Human retinal pigment epithelial (RPE) cells produce levodopa and their transplantation into the striatum might improve continuity of administration compared with that achieved with oral levodopa...
  69. doi Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia
    M Carta
    Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17, 22184 Lund, Sweden
    Neuroscience 198:245-51. 2011
    ....
  70. doi Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning
    Adjmal Nahimi
    Center of Functionally Integrative Neuroscience, Aarhus University Hospitals, Aarhus University, Denmark
    J Neurochem 120:806-17. 2012
    ....
  71. pmc The subthalamic microlesion story in Parkinson's disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRI
    Robert Jech
    Dept of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
    PLoS ONE 7:e49056. 2012
    ..The fMRI was carried out after an overnight withdrawal of levodopa (OFF condition): (i) before and (ii) within three days after surgery in absence of neurostimulation...
  72. doi Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 28:1064-71. 2013
    The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's ..
  73. ncbi Rat liver aromatic L-amino acid decarboxylase: spectroscopic and kinetic analysis of the coenzyme and reaction intermediates
    H Hayashi
    Department of Biochemistry, Osaka Medical College, Japan
    Biochemistry 32:812-8. 1993
    ..These predicted absorption spectra of X1 and X2 showed striking resemblances to those of AADC complexed with dihydroxyphenylacetic acid (DOPAc) and L-dopa methyl ester (DopaOMe), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)..
  74. ncbi Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease
    A Priori
    Department of Neurological Sciences, IRCCS Ospedale Maggiore di Milano, Universita di Milano, 20122 Milan, Italy
    Exp Neurol 189:369-79. 2004
    ..were recorded at rest both before (off) and after (on) acute administration of different antiparkinsonian drugs: levodopa, apomorphine, or orphenadrine...
  75. ncbi Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
    Giovanna Levandis
    Laboratory of Functional Neurochemistry, Interdepartmental Research Center for Parkinsons s Disease CRIMP, IRCCS C Mondino, Pavia, Italy
    Neurobiol Dis 29:161-8. 2008
    ..Our data confirm the role of glutamatergic neurotransmission in the pathogenesis of dyskinesias and the potential of mGluR5 antagonists in the treatment of l-DOPA-induced dyskinesias...
  76. doi Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments
    Elmyra V Encarnacion
    Department of Neurology, Texas A and M Health Sciences Center, Scott and White National Parkinson Foundation Plummer Movement Disorders Center, Temple, TX, USA
    Eur Neurol 60:57-66. 2008
    b>Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias...
  77. pmc The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats
    Karen L Eskow
    Behavioral Neuroscience Program, Department of Psychology, State University of New York at Binghamton, Binghamton, New York 13902 6000, USA
    Synapse 63:610-20. 2009
    ..These current findings reveal the integral contribution of the RRN in the development and expression of LID and implicate a prominent role for dorsal raphe 5-HT1AR in the efficacious properties of 5-HT1AR agonists...
  78. pmc Axial kinesthesia is impaired in Parkinson's disease: effects of levodopa
    W G Wright
    Department of Physical Therapy, Temple University, Philadelphia, PA 19140, USA
    Exp Neurol 225:202-9. 2010
    ..The relation of kinesthetic threshold to disease progression as measured by UPDRS and the effect of levodopa treatment on kinesthesia were assessed in 12 PD compared to age-matched controls...
  79. doi Motor complications, levodopa metabolism and progression of Parkinson's disease
    Thomas Muller
    St Joseph Hospital Berlin Weissensee, Department of Neurology, Gartenstr 1, 13088 Berlin, Germany
    Expert Opin Drug Metab Toxicol 7:847-55. 2011
    ..Clinically, progression of PD is also characterised by onset of motor complications (MC). MC results from the peripheral and central degree of fluctuations of levodopa (LD) and of dopamine.
  80. doi Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
    Christopher Kobylecki
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Mov Disord 26:2354-63. 2011
    ..These data confirm the antidyskinetic potential of topiramate and suggest that combination with low-dose amantadine may allow better reduction of dyskinesia with no adverse motor effects...
  81. ncbi Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation
    K Kannari
    Third Department of Medicine and Department of Neurology, Hirosaki University School of Medicine, Hirosaki, Japan
    J Neurochem 76:1346-53. 2001
    ..These results support the hypothesis that serotonergic neurons are primarily responsible for the storage and release of DA derived from exogenous L-DOPA in the absence of dopaminergic neurons...
  82. pmc Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries
    M M Lewis
    Department of Neurology, University of North Carolina, Chapel Hill, NC 27599 7125, USA
    Neuroscience 147:224-35. 2007
    ..were no significant differences between the twins in bilateral BG-cortical pathways, either basally or after levodopa, whereas the PD-twin had relatively increased activity in the cerebellar-cortical pathways basally that was ..
  83. doi Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease
    A Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italia
    Neurodegener Dis 5:244-6. 2008
    ..PD) continue to experience motor fluctuations and dyskinesias despite the association of dopamine agonists and levodopa with COMT or MAO-B inhibitors...
  84. doi Focusing effects of L-dopa in Parkinson's disease
    Bernard Ng
    Department of Electrical and Computer Engineering, The University of British Columbia, Vancouver, Canada
    Hum Brain Mapp 31:88-97. 2010
    ..This observation is consistent with modeling studies, which demonstrated that dopamine increases the signal-to-noise ratio at the neuronal level with a resultant focusing of representations at the macroscopic level...
  85. doi Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
    Nicolas Morin
    Molecular Endocrinology and Genomic Research Center, Laval University Medical Center CHUL, 2705 Laurier Blvd, Quebec QC, Canada
    Neuropharmacology 58:981-6. 2010
    ..This supports the therapeutic use of an mGluR5 antagonist to restore normal brain glutamate neurotransmission in PD and decrease dyskinesias...
  86. doi The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease
    Fabrizio Stocchi
    Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Parkinsonism Relat Disord 15:S68-71. 2009
    ..to discontinuous or pulsatile, stimulation of striatal dopamine receptors will delay or prevent the onset of levodopa-related motor complications...
  87. doi Malnutritional neuropathy under intestinal levodopa infusion
    Fabian Klostermann
    Deptartment of Neurology, CBF, Charite University Medicine Berlin, Hindenburdamm 30, 12203 Berlin, Germany
    J Neural Transm (Vienna) 119:369-72. 2012
    b>Levodopa/Carbidopa intestinal gel infusion (LCIG) for Parkinson's disease is under debate to provoke polyneuropathy (PNP)...
  88. ncbi Subthalamotomy for advanced Parkinson disease
    Philip C Su
    Department of Neurology, National Taiwan University Hospital, Taipei, ROC
    J Neurosurg 97:598-606. 2002
    ..The aim of this study was to determine if subthalamotomy is effective in treating advanced Parkinson disease (PD)...
  89. pmc Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease
    Janne Ludwig
    Division of Neurological Pain Research and Therapy, University of Kiel, Kiel, Germany
    J Neurol Neurosurg Psychiatry 78:742-5. 2007
    ..whether STN stimulation has an influence on functions of the ANS and to compare these effects to those induced by levodopa. Blood pressure (BP) and heart rate (HR) during rest and orthostatic conditions, HR variability (HRV) and ..
  90. doi L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease
    Jorge Guridi
    Division of Neurosurgery, Neuroscience Department, University Clinic, University of Navarra, Pamplona, Spain
    Neurosurgery 62:311-23; discussion 323-5. 2008
    ..To assess the impact of different surgical targets and techniques, such as ablation and deep brain stimulation, to treat patients with L-dopa-induced dyskinesia (LID), a major therapeutic complication of Parkinson's disease...
  91. pmc Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease
    MoonHee Lee
    Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    J Biol Chem 285:17318-28. 2010
    The main lesion in Parkinson disease (PD) is loss of substantia nigra dopaminergic neurons. Levodopa (L-DOPA) is the most widely used therapy, but it does not arrest disease progression...
  92. pmc Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
    Kristin B Dupre
    Behavioral Neuroscience Program, Department of Psychology, Binghamton University State University of New York at Binghamton, Binghamton, NY 13902 6000, USA
    Exp Neurol 229:288-99. 2011
    ..These findings indicate a novel anti-dyskinetic mechanism of action for 5-HT(1A)R agonists with implications for the improved treatment of Parkinson's disease...
  93. ncbi Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene
    H Ichinose
    Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan
    Nat Genet 8:236-42. 1994
    ..dystonia) is a dystonia with onset in childhood that shows a marked response without any side effects to levodopa. Recently the gene for dopa responsive dystonia (DRD) was mapped to chromosome 14q...
  94. ncbi 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy
    S L Nicholson
    University of Manchester, School of Biological Sciences, UK
    Eur J Neurol 9:1-6. 2002
    ..g. wearing-off and levodopa-induced dyskinesia) have identified 5-HT1A, 5-HT1B and 5-HT2C receptors as potential therapeutic targets in ..
  95. ncbi Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease
    Antonella Peppe
    Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Santa Lucia, Clinica Neurologica and Servizio di Neurofisiopatologia Policlinico, Universita Tor Vergata, Rome, Italy
    J Neurosurg 101:195-200. 2004
    ....
  96. ncbi Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners
    Miet De Letter
    Department of Oto Rhino Laryngology, Centre of Speech and Hearing Disorders, Ghent University Hospital, Ghent, Belgium
    Clin Linguist Phon 21:783-91. 2007
    ..Few data on the effects of levodopa on prosody, more specifically on the effects on the variability of prosodic characteristics such as pitch, ..
  97. doi Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms
    M Giorgi
    Department of Basic and Applied Biology, L Aquila University, L Aquila, Italy
    Eur J Neurosci 28:941-50. 2008
    Dysregulation of dopamine receptors is thought to underlie levodopa-induced dyskinesias in experimental models of Parkinson's disease...
  98. doi Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
    Manon Lebel
    Groupe de Recherche en Neurosciences, Departement de Chimie Biologie, Universite du Quebec a Trois Rivieres, 3351, boul des Forges, C P 500, Trois Rivieres, QC, Canada G9A 5H7
    Neurobiol Dis 38:59-67. 2010
    ....
  99. pmc Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements
    Xuebing Cao
    Department of Neurology, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    J Neurosci 30:7335-43. 2010
    ..DeltaFosB overexpression reproduced the entire spectrum of altered motor behaviors in response to acute levodopa tests, including different types of abnormal involuntary movements and hypersensitivity of rotational responses ..
  100. doi Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia
    Bai Yun Zeng
    NDRG, School of Biomedical and Health Sciences, King s College, London, UK
    Neurobiol Dis 40:599-607. 2010
    ..Recent studies have suggested that non-physiological release of dopamine (DA) formed from levodopa in these serotoninergic terminals underlies abnormal involuntary movement (AIMs) induction in 6-OHDA lesioned ..

Research Grants74

  1. Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and Disease
    John J Mieyal; Fiscal Year: 2012
    ..L-dihydroxyphenylalanine (levodopa, L-DOPA) is the drug of choice for treatment of the symptoms of this disease, serving to replenish dopamine...
  2. A Phase II Trial of Levodopa in Angelman Syndrome
    Wen Hann Tan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): This study will investigate the efficacy of levodopa in improving the neurodevelopment and movement disorders in children with Angelman Syndrome (AS), a rare neurodevelopmental disorder with a ..
  3. Miguel A L Nicolelis; Fiscal Year: 2014
    ..and rotating rod tests will be used to evaluate their motor function and compare it to a sham treated group and a levodopa treated group...
  4. A Conserved G-rich Region within Human TH Promoter Regulates Its Activity
    Soumitra Basu; Fiscal Year: 2011
    ..with a broad spectrum of phenotype ranging from TH-deficient dopa-responsive dystonia (DRD) at the mild end to a levodopa-unresponsive infantile parkinsonism or progressive infantile encephalopathy phenotype at the severe end...
  5. Characterization of Striatal Nitric Oxide Signaling
    Anthony West; Fiscal Year: 2009
    ..and may underlie adaptive changes in basal ganglia circuits observed following prolonged treatment with levodopa (L-DOPA)...
  6. Neural Substrates of Oral Motor Dysfunction in Parkinson's Disease
    EMILY KATE PRINE; Fiscal Year: 2010
    ..Animals will then receive either 1) oral motor therapy;2) oral motor therapy + levodopa;3) upper extremity therapy;4) upper extremity therapy + levodopa;5) levodopa therapy;or 6) no rehabilitation for ..
  7. A Novel Monkey Model for Parkinson's Drug Discovery
    Howard J Federoff; Fiscal Year: 2010
    ..be followed longitudinally by 18fluoro-methyl tyrosine PET imaging and a Clinical Rating Scale (CRS) off and on levodopa and apomorphine...
  8. KATHRYN ANNE CHUNG; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most patients with Parkinson disease(PD) as a consequence of chronic use of the most effective symptomatic drug, ..
  9. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Levodopa therapy - the gold standard in Parkinson's disease (PD) treatment - causes disabling motor complications (dyskinesias) that are largely resistant to available drugs...
  10. JOY MARIE SCHMITZ; Fiscal Year: 2014
    ..DA enhancement therapy that targets cocaine use and cognitive deficits by combining two dopaminergic medications: levodopa and ropinirole...
  11. DANIEL OLIVER CLAASSEN; Fiscal Year: 2016
    PROJECT SUMMARY Dopamine (DA) therapy used for the treatment of Parkinson Disease (PD) consists of Levodopa and Dopamine receptor Agonist (DAA) medications...
  12. Robert Folmer; Fiscal Year: 2015
    ..PD patients who take levodopa daily will undergo study procedures in the morning, within 3 hours of ingesting the medication...
  13. JOSEPH GIUFFRIDA; Fiscal Year: 2014
    ..Treatments include pharmaceutical interventions such as levodopa and surgical procedures such as deep brain stimulation (DBS)...
  14. CHRISTOPHER LEE PULLIAM; Fiscal Year: 2014
    ..a wireless, ergonomic, and portable movement disorder technology designed for continuous monitoring of levodopa-induced dyskinesia (LID) and medication state in Parkinson's disease (PD)...
  15. Striatal Origin of Pathological Beta Oscillations in Parkinson's Disease
    Xue Han; Fiscal Year: 2013
    ..Anti-cholinergic drugs, the only available drugs for PD before the development of levodopa treatment in the 1970s, remain to be in clinical use today...
  16. Limited Competition for Continuation of the NIH Exploratory Trials in PD
    Oksana Suchowersky; Fiscal Year: 2013
    ..There is no cure and etiology is unknown. Medications such as levodopa provide good benefit for a number of years...
  17. Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome
    KATHY STEECE STEECE-COLLIER; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Despite the undeniable benefit of levodopa, symptomatic treatment for Parkinson's disease (PD) remains suboptimal...
  18. Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's Dis
    Nurulain T Zaveri; Fiscal Year: 2010
    ..Dopamine replacement therapy with Levodopa (L-Dopa) is currently the standard pharmacotherapy for PD, but unfortunately, continued therapy with L-Dopa ..
  19. Manfred Lindau; Fiscal Year: 2014
    ..In the treatment of Parkinson's disease the drug levodopa increases dopamine release from the reduced number of dopaminergic neurons...
  20. Continuation of NET-PD Trials at University of Miami Miller School of Medicine
    Carlos Singer; Fiscal Year: 2013
    ..blind, placebo controlled trial tested against the background of dopaminergic therapy (dopamine agonists and levodopa) and best PD care...
  21. Biomarkers for Preclinical Parkinson's disease
    Jing Zhang; Fiscal Year: 2012
    ..g. bradykinesia, rigidity, and tremor, and show favorable response to levodopa (L-DOPA) or dopamine (DA) agonists...
  22. David Eidelberg; Fiscal Year: 2014
    ..Project 1 addresses the serious clinical problem of levodopa-induced dyskinesias, which ultimately affect nearly all PD patients...
  23. Kinesia-D: Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Tit
    THOMAS OLIVER MERA; Fiscal Year: 2011
    ..wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced choreatic dyskinesias, or irregular rapid involuntary movements, in Parkinson's disease (PD)...
  24. Thomas Piccariello; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Synthonics is developing the metal-coordinated levodopa drug product, MCP-311, for FDA approval...
  25. Mechanisms of Movement Facilitation and Release by Cueing in Parkinson's disease
    Colum D MacKinnon; Fiscal Year: 2013
    ..disease progression, akinesia, start hesitation and FOG often becomes refractory to current treatments such as levodopa and deep brain stimulation. Currently there are no effective treatments for these symptoms...
  26. Stella M Papa; Fiscal Year: 2016
    ..shown that the striatal levels of the chronic transcription factor (FosB consistently increase during chronic levodopa treatment...
  27. REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
    Stella M Papa; Fiscal Year: 2013
    ..drugs in striatal injections or infusions to study the effects on striatal neurons and motor responses to levodopa. 3...
  28. Validation of PPARgamma agonists as anti-dyskinetic drugs
    Alex Anthony Martinez; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Levodopa (L-DOPA) remains the gold standard therapy for Parkinson's disease (PD) treatment, but it's long- term use is associated with disabling side effects consisting of uncontrolled ..
  29. PERIPHERAL AND CENTRAL POSTURAL DISORDERS IN THE ELDERLY
    FAY BAHLING HORAK; Fiscal Year: 2013
    ..All studies will test subjects with PD in the ON and OFF states to examine the effects of levodopa replacement on kinesthetic control of posture...
  30. Breath Test for Individualizing CD Therapy in Parkinson Disease
    David I Rosen; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Response to carbidopa/levodopa (CD/LD), the most efficacious therapy in Parkinson's disease (PD), is often variable among patients...
  31. JOEL SYNES PERLMUTTER; Fiscal Year: 2016
    ..In addition, we will test the hypothesis that acute or chronic administration of levodopa or the dopamine agonist pramipexole may alter selected neuroimaging biomarkers...
  32. LRRK2 and RhoGTPases: Local translation in neurodegeneration
    Diane Chan; Fiscal Year: 2012
    ..Now, more than 50 years after the discovery and use of levodopa for symptomatic treatment of Parkinsonian symptoms, we still do not have a disease-modifying drug for the ..
  33. TESTING THE PHASIC DOPAMINE RELEASE HYPOTHESIS IN TOURETTE SYNDROME: PILOT
    TAMARA G HERSHEY; Fiscal Year: 2013
    ..release in TS by measuring striatal dopamine release in response to a cognitive task with and without exogenous levodopa. The proposal will exploit the newly developed Siemens PET-MRI scanner to acquire rCBF simultaneously with the ..
  34. Evaluating BMY-14802 as an anti-dyskinesia treatment in the 6-OHDA rat model of P
    MELANIE PAQUETTE; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Our objective is to develop new drug treatments for the side effects of levodopa (L-DOPA) that occur in people with Parkinson's Disease...
  35. Axonal Degeneration in LRRK2 Parkinson?s Disease
    Chenjian Li; Fiscal Year: 2010
    ..These mice develop an age-dependent progressive decrease in motor activity that is responsive to treatment with levodopa. At the level of pathology, the early and most robust phenotype is the axonopathy of the nigrostriatal ..
  36. Carbidopa for the treatment of nausea and vomiting in familial dysautonomiaIND #
    Horacio Kaufmann; Fiscal Year: 2010
    ..synthesis of dopamine and avoid nausea and vomiting in patients with Parkinson's disease taking levodopa. The investigators reason that carbidopa could have a similar antiemetic effect in patients with FD...
  37. CIRCULATORY CONTROL IN CHRONIC HYPOTENSIVE STATES
    ROSE ROBERTSON; Fiscal Year: 1990
    ..We will use similar methods to explore the role of central alpha2-adrenoreceptors in the orthostatic hypotension produced by levodopa therapy.
  38. Functional Studies of Subtypes of Parkinson's Diseasee
    Xuemei Huang; Fiscal Year: 2007
    ..as tremor-predominant PD (PDT) generally has better long-term motor outcome with fewer motor fluctuations, less levodopa-induced dyskinesias, a slower rate of progression, and fewer cognitive deficits when compared with akinetic-rigid-..
  39. Parkinson Disease Neuroprotective Trial: Clinical Center
    Brad A Racette; Fiscal Year: 2013
    ..Secondary analyses include individual components of the primary outcome measure, use of health services, levodopa-dose equivalents, safety, and tolerability...
  40. CLINICAL PHARMACOLOGY CENTER
    Michael Murphy; Fiscal Year: 1991
    ..The goal of Project IV "Role of DA Receptors in Hypertension" is to determine whether levodopa can serve as a prodrug for DA and will reverse renal deterioration observed in hypertensive patients...
  41. Motor Learning in Parkinson's Disease
    M Ghilardi; Fiscal Year: 2002
    ..Specifically, we will pursue the following aims: 1. To study the effects of DBS and levodopa administration on motor learning in PD...
  42. NEUROIMAGING OF HYPERKINETIC MOVEMENT DISORDERS
    Michael Hutchinson; Fiscal Year: 2001
    ..cerebral glucose metabolism and blood flow: blepharospasm, idiopathic torsion dystonia, Huntington's chorea and levodopa-induced dyskinesia...
  43. Dopaminergic Effects on Cortical Function in Tourette's
    Kevin J Black; Fiscal Year: 2010
    ..of several brain regions, but the excessive activation normalized after administration of the dopamine precursor levodopa. This drug is well suited for neuroimaging studies as it is well tolerated in TS and (when given with carbidopa) ..
  44. Levodopa Pharmokinetic Optimization by Metal Coordination
    Thomas Piccariello; Fiscal Year: 2009
    ..by applicant): Synthonics is interested in applying metal coordination chemistry to the dopamine precursor levodopa. This biochemical has served as the primary symptomatic pharmacotherapy for patients with Parkinson's ..
  45. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2005
    ..b>levodopa, dopamine agonists)...
  46. Parkinson's Disease Gene Therapy Study Group
    Howard Federoff; Fiscal Year: 2006
    Parkinson's disease (PD) affects about 1 million people in North America. Medications, such as levodopa, and some surgical approaches are available for PD, but offer only symptomatic therapy...
  47. Jay L Alberts; Fiscal Year: 2015
    ..patients produces a similar subcortical and cortical pattern of activation as is seen following administration of levodopa. Global improvements in motor function and increased neural activity suggest forced-exercise may be altering ..
  48. EFFECTS OF DBS ON POSTURE AND OROMOTOR CONTROL
    Fay Horak; Fiscal Year: 2005
    ..In many patients, these "axial symptoms" are resistant to levodopa therapy...
  49. GLUTAMATE IN PARKINSON'S DISEASE
    J Greenamyre; Fiscal Year: 2003
    ..Compare the development and severity of dyskinesias in de novo parkinsonian monkeys treated chronically with (1) levodopa alone, or (2) a combination of levodopa and an NMDA antagonist. 4...
  50. Control of Repetitive Movement in Parkinson's Disease
    Colum MacKinnon; Fiscal Year: 2009
    ..to impaired repetitive movement in patients with PD and the effects of the two most successful treatments for PD, levodopa and high frequency stimulation of the subthalamic nucleus (STN-DBS), on these mechanisms...
  51. Levodopa dyskinesia and striatal neuroplasticity
    Christine Konradi; Fiscal Year: 2007
    ..Patients with Parkinson's disease are treated with levodopa (L-DOPA), a precursor of dopamine. However, L-DOPA therapy has disabling side effects...
  52. BIOMETRIC INSTRUMENT TO MONITOR NEUROLOGICAL DISORDERS
    RUTH SHRAIRMAN; Fiscal Year: 2009
    ..tested on Parkinson's patients in the pilot experimental studies on measuring the effects of the levodopa treatment on motor fluctuations, and on detecting of the ipsilateral motor control impairment in patients with ..
  53. MECHANISM OF TREATMENT COMPLICATIONS IN PARKINSONS
    Robert Schwartzman; Fiscal Year: 1991
    ..motor complications ("peak-dose" dyskinesia and "end of dose" failure) in MPTP parkinsonian monkeys treated with levodopa (L-dopa)...
  54. Mucana Pruriens for dyskinesias in Parkinson's disease
    Thyagarajan Subramanian; Fiscal Year: 2006
    ..daily dose of Mucuna pruriens for 30 days prior to treatment with intermittant high doses of methyl ester of levodopa/benseraside to induce dyskinesias...
  55. A new Instrument to Quantify Dyskinesia In Patients with Parkinson's Disease
    Patrick Lichter; Fiscal Year: 2006
    ..Recently there has been interest in quantifying dyskinesia, a side effect of the levodopa that is used to reduce Parkinsonian symptoms, for the evaluation of pharmacological and surgical interventions ..
  56. AXON GUIDANCE IN THE SPINAL CORD
    Jane Dodd; Fiscal Year: 2004
    ..abstract_text> ..
  57. Intranigral Transplantation in Parkinsonian Monkeys
    Thyagarajan Subramanian; Fiscal Year: 2010
    ..All animals will be treated with levodopa to induce drug induced dyskinesias and periodically tested using a behavioral battery of tests (BBT) to assess ..
  58. Enzymatic Replacement in PD Monkeys by Gene Transfer
    Krystof Bankiewicz; Fiscal Year: 2003
    ..the MPTP-treated Parkinsonian primate model: (i) evaluate clinical efficacy of AADC gene transfer combined with levodopa administration; (ii) evaluate the efficacy of AAV/AADC gene transfer aimed at alleviating levodopa-induced ..
  59. DEPRENYL/TOCOPHEROL ANTIOXIDATIVE THERAPY OF PARKINSON'S
    Ira Shoulson; Fiscal Year: 1991
    ..deprenyl and/or tocopherol administration to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat supervening disability...
  60. DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS
    Jeffrey Kordower; Fiscal Year: 2006
    ..that these dyskinesias result from local "hot spots" of hyperdopaminergic function interacting with the levodopa primed brain...
  61. Earlier vs. Later Levodopa in Parkinson's Disease
    Stanley Fahn; Fiscal Year: 2002
    ..placebo-controlled, parallel-design multi-center clinical trial was developed to determine the impact, if any, of levodopa on the natural history of Parkinson's disease (PD)...
  62. Vocalization deficits in parkinson rats: Does L-DOPA harm or help therapy?
    MICHELLE CIUCCI; Fiscal Year: 2009
    ..Upon diagnosis, the primary form of intervention is the introduction of pharmacotherapy, primarily levodopa. However, in the early stages of PD, administration of levodopa is controversial...
  63. Peripheral Inosine Treatment in a Rodent Model of Parkinson's
    BRIAN TERPSTRA; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Dopamine (DA) replacement in Parkinson's Disease (PD) via levodopa therapy lacks long term efficacy and results in debilitating side effects...
  64. Levodopa-Induced Plasticity in the Basal Ganglia
    Kirsten Nielsen; Fiscal Year: 2003
    b>Levodopa (L-dopa) remains the most effective drug treatment for the symptomatic relief of Parkinson's disease...
  65. Study of L-Dopa in ADHD and RLS/PLMS
    Arthur Walters; Fiscal Year: 2004
    This revised application proposes a pilot multicenter randomized placebo-controlled clinical trial of levodopa in children with ADHD both with and without periodic limb movements of sleep (PLMS) and restless legs syndrome (RLS)...
  66. NMDA RECEPTORS--REGULATION OF BASAL GANGLIA FUNCTION
    David Standaert; Fiscal Year: 2004
    ..that changes in NMDA receptor properties may be responsible for the development of the motor complications of levodopa therapy, such as wearing off and dyskinesias...